
|Videos|July 7, 2021
Why Research Assessing Dapagliflozin Advanced From Cardiorenal Effects to Prevention, Organ Protection
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Adds a New Sunscreen to the OTC Repertoire
2
EPCORE DLBCL-1 Trial Demonstrates Durable Responses, PFS Benefit With Epcoritamab in RR LBCL
3
Gemcitabine Intravesical System: A Novel Treatment Option for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
4
NLA 2026: Evolocumab Cuts Cardiovascular Events in High-Risk Patients Before First MI or Stroke
5






























































































































